Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

SMN gene therapy can result in too much of a good thing

April 8, 2021

Subcutaneous injection of Tysabri approved in Europe for relapsing-remitting MS

April 8, 2021

Vincere Biosciences presents new USP30 inhibitors

April 8, 2021

Recognify Life Sciences initiates phase IIa trial of RL-007 in CIAS

April 7, 2021

Oryzon announces preclinical collaboration with Seaver Autism Center at Mount Sinai

April 7, 2021

Japanese investigators identify P2X4 receptor antagonists

April 7, 2021

U.S. researchers patent protein kinase inhibitors

April 7, 2021

Antibodies could make things worse in neurodegeneration

April 7, 2021

C3aR is a potential therapeutic target in vascular cognitive impairment

April 7, 2021

Azafaros initiates phase I study of AZ-3102 for rare neurogenetic disorders

April 6, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis
BioWorld
Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements...